Aevi Genomic Medicine, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced operating loss was USD 3.649 million compared to USD 8.251 million a year ago. Net loss was USD 3.645 million compared to USD 8.191 million a year ago. Basic loss per share was USD 0.06 compared to USD 0.14 a year ago. For the half year, operating loss was USD 8.503 million compared to USD 16.986 million a year ago. Net loss was USD 8.484 million compared to USD 16.900 million a year ago. Basic loss per share was USD 0.13 compared to USD 0.28 a year ago.